This research aims to evaluate the effects of omitting hyperthermic intraperitoneal chemotherapy (HIPEC) during treatment for colorectal peritoneal metastases (CPM).
Evaluated short-term oncologic outcomes after cytoreductive surgery (CRS) with and without HIPEC.
Compared morbidity associated with each treatment approach.
Analyzed long-term benefits of HIPEC, if any.
Omission of HIPEC did not result in significant morbidity.
Short-term oncologic benefits were found to be equivalent between groups.
Long-term benefits of HIPEC remain uncertain.
Abstract
CRS with mitomycin-HIPEC can be considered for treatment of CPM without significant morbidity and equivalent short-term oncologic benefits. However, the long-term benefit of HIPEC remains unclear.
AIに質問
Like
Bookmark
Share
View Full Paper
AIに質問
Like
Bookmark
Share
View Full Paper
Impact of Omission of Hyperthermic Intraperitoneal Chemotherapy for Treatment of Colorectal Peritoneal Metastases | Synapse